A phase II clinical trial was conducted to evaluate the efficacy of intravenous fluorouracil in the treatment of HCC; i.v. fluorouracil was well tolerated and induced a durable partial response in 31% (5 of 16) of patients with HCC who had low levels of serum AFP; and the treatment regimen was ineffective in patients with HCC who had high levels of serum AFP [21]. Here, AFP is linked to hepatocellular carcinoma.